Ken Griffin Biodesix Inc Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.21 - $1.71 $605 - $855	500 New	500 $0
Q4 2023 Feb 14, 2024	SELL	$1.2 - $2.13 $1,800 - $3,195	-1,500 Reduced 65.22%	800 $1,000
Q3 2023 Nov 14, 2023	BUY	$1.04 - $1.74 $2,392 - $4,002	2,300 New	2,300 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.98 - $2.3 $33,320 - $78,200	-34,000 Reduced 97.42%	900 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.24 - $2.89 $41,788 - $97,393	-33,700 Reduced 49.13%	34,900 $44,000

53.6M

500

11.5K

Ticker BDSX
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 39,982,000
Market Cap $71.6M
Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.